Results 81 to 90 of about 28,079 (244)
Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022
HIV Medicine, EarlyView.Abstract Introduction
This study provides a comprehensive overview of HIV care by combining cross‐sectional and longitudinal continuum of care (CoC) analyses. Methods
Using national surveillance data 2014–2022, a five‐stage cross‐sectional CoC was calculated among people living with HIV (incl.D. Van Beckhoven, B. Serrien, R. Demeester, J. Van Praet, P. Messiaen, G. Darcis, S. Henrard, P. De Munter, A. Libois, J. Deblonde +9 morewiley +1 more sourceLEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. [PDF]
PLoS Pathogens, 2012 Lens epithelium-derived growth factor (LEDGF/p75) is a cellular cofactor of HIV-1 integrase (IN) that interacts with IN through its IN binding domain (IBD) and tethers the viral pre-integration complex to the host cell chromatin.Rik Schrijvers, Jan De Rijck, Jonas Demeulemeester, Noritaka Adachi, Sofie Vets, Keshet Ronen, Frauke Christ, Frederic D Bushman, Zeger Debyser, Rik Gijsbers +9 moredoaj +1 more sourceAntiretroviral therapy use, self‐reported adherence, and viral suppression among women living with HIV in Canada
HIV Medicine, EarlyView.Abstract Background
Traditionally, ≥95% adherence was recommended for viral suppression (VS). Newer antiretroviral therapy (ART) is now being increasingly prescribed and may be more forgiving of lower adherence. The lifelong nature of ART presents adherence challenges, particularly for women living with HIV. We aimed to describe ART use and examine the Maysaloun Mokaddam, Nadine Kronfli, Nancy L. Sheehan, Araceli Gonzalez Reyes, Danièle Dubuc, Mona Loutfy, Angela Kaida, Alexandra de Pokomandy, on behalf of the CHIWOS research team, Rahma Abdul‐Noor, Aranka Anema, Jonathan Angel, Dada Mamvula Bakombo, Fatimatou Barry, Greta Bauer, Kerrigan Beaver, Marc Boucher, Isabelle Boucoiran, Jason Brophy, Lori Brotto, Ann N. Burchell, Claudette Cardinal, Allison Carter, Lynne Cioppa, Tracey Conway, José Côté, Jasmine Cotnam, Cori d'Ambrumenil, Janice Dayle, Erin Ding, Danièle Dubuc, Janice Duddy, Mylène Fernet, Annette Fraleigh, Peggy Frank, Brenda Gagnier, Marilou Gagnon, Jacqueline Gahagan, Claudine Gasingirwa, Nada Gataric, Rebecca Gormley, Saara Greene, Danielle Groleau, Charlotte Guerlotté, Trevor Hart, Catherine Hankins, Emily Heer, Robert S. Hogg, Terry Howard, Shazia Islam, Joseph Jean‐Gilles, Hermione Jefferis, Evin Jones, Charu Kaushic, Mina Kazemi, Mary Kestler, Maxime Kiboyogo, Marina Klein, Nadine Kronfli, Gladys Kwaramba, Gary Lacasse, Ashley Lacombe‐Duncan, Melanie Lee, Rebecca Lee, Jenny Li, Viviane Lima, Elisa Lloyd‐Smith, Carmen Logie, Evelyn Maan, Valérie Martel‐Lafrenière, Carrie Martin, Renee Masching, Lyne Massie, Melissa Medjuck, Brigitte Ménard, Cari L. Miller, Judy Mitchell, Gerardo Mondragon, Deborah Money, Ken Monteith, Marvelous Muchenje, Florida Mukandamutsa, Mary Ndung'u, Valerie Nicholson, Kelly O'Brien, Nadia O'Brien, Gina Ogilvie, Susanna Ogunnaike‐Cooke, Joanne Otis, Rebeccah Parry, Sophie Patterson, Angela Paul, Doris Peltier, Neora Pick, Alie Pierre, Jeff Powis, Karène Proulx‐Boucher, Corinna Quan, Jesleen Rana, Eric Roth, Danielle Rouleau, Geneviève Rouleau, Sergio Rueda, Kate Salters, Margarite Sanchez, Roger Sandre, Jacquie Sas, Édénia Savoie, Paul Sereda, Stephanie Smith, Marcie Summers, Wangari Tharao, Christina Tom, Cécile Tremblay, Jason Trigg, Sylvie Trottier, Angela Underhill, Anne Wagner, Sharon Walmsley, Clara Wang, Kath Webster, Wendy Wobeser, Denise Wozniak, Mark H. Yudin, Wendy Zhang, Julia Zhu +125 morewiley +1 more sourcePrevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan. [PDF]
Sci RepHIV acquisition has been found to be associated with increased risk of cardiometabolic syndrome in the past. In this study, we attempt to delineate the associated factors of metabolic syndrome among persons living with HIV in a single medical center in ...Tu CA, Kuo CF, Lee CM, Liu CP, Tseng HK, Huang TY, Lin CC, Chang H, Lee WY, Sun FJ, Sun ZY, Lian PC, Cheng MW, Wu AY. +13 moreeuropepmc +2 more sourcesEffectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]
, 2019 Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...Abeli C., Acinapura R., alungo A., Andreoni M., Angarano G., Antinori A., aracino A., atini A., azzarin A., Bagella P., Bai F., Baldelli F., Baldin G., Balotta C., Bandera A., Barocci V., Bassetti M., Blanc P., Bobbio N., Bonfanti P., Bonora S., Borderi M., Borgia G., Cacopardo B., Calcagno A., Capetti A., Capobianchi M. R., Capozzi M., Caramello P., Carletti F., Carrara S., Cascio A., Cassola G., Castagna A., Castelli F., Castelnuovo F., Cattelan A. M., Cauda R., Ceccherini-Silberstein F., Ceccherini-Silberstein F., Cecchetto M., Celesia B., Chiodera A., Cicalini S., Cingolani A., Cinque P., Colomba C., Costantini A., Cozzi-Lepri A., Cozzi-Lepri A., Cristaudo A., d'Arminio Monforte A., De Luca A., Di Biagio A., Di Caro A., Di Giuli C., Di Martino F., Di Perri G., Esposito V., Fabrizio C., Falasca K., Fanti I., Fontana Del Vecchio R., Francisci D., Galli L., Galli M., Gentile I., Giacometti I. A., Gianotti N., Girardi E., Gori A., Graziano S., Guaraldi G., i V., Iaiani G., Iardino R., Ippolito G., Lapadula G., lessandrini A., Lichtner M., Lo Caputo S., Lorenzini P., Lorenzotti S., Macchia M., Maddaloni L., Madeddu G., Maggiolo F., Maggiolo F., Magnani G., Manfrin V., Marchetti G., Marinello S., Mastrorosa I., Mazzarello G., Menzaghi B., Migliorino C., Milini P., Minardi C., Moioli M. C., Molteni C., Mondi A., Monno L., Mussini C., Nozza S., Nunnari G., ondero A., Orofino G. C., Pan A., Parruti G., Pellicano G., Pellizzer G., Perno C. F., Petrone F., Piolini R., Plazzi M. M., Pozzetto I., Prota G., Puoti M., Puzzolante C., Quartu S., Quiros Roldan E., Rezza G., Ridolfo A. L., Rivano Capparucia M., Rizzardini G., Rodano' A., Rossetti B., Rossotti R., Rusconi S., Rusconi S., Salpietro S., Sangiovanni V., Santoro M. M., Sarmati L., Savinelli S., Schiaroli E., Sciandra M., Segala D., Sighinolfi L., Sozio F., Starnini G., Suardi C., Tavelli A., Tavelli A., Tincati C., Truffa S., Ursitti M. A., Vecchiet J., Vergori A., Verucchi G., Viale P., Vichi F., Viscoli C., Viviani F., von Schloesser F., Vullo V. +155 morecore +4 more sourcesMetabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)‐Heart study
HIV Medicine, EarlyView.Abstract Background
Limited data exist describing metabolic syndrome (MetS) and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores in youth with HIV in sub‐Saharan Africa.Sahera Dirajlal‐Fargo, Mothabisi Nyathi, Shan Sun, Lauren Balmert Bonner, Morné Kahts, Nana Akua Asafu‐Agyei, Nomawethu Jele, Emma Carkeek, Justine Legbedze, Grace A. McComsey, Matthew Feinstein, Landon Myer, Ntobeko A. B. Ntusi, Heather J. Zar, Jennifer Jao +14 morewiley +1 more sourceUrinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. [PDF]
, 2014 Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.Boger, M Sean, Currier, Judith S, Hulgan, Todd, Lake, Jordan E, Liao, Diana H, Mangili, Alexandra, McComsey, Grace A, McCreath, Heather, Milne, Ginger L, Sanchez, Stephanie C, Walmsley, Sharon L, Wanke, Christine A +11 morecore +3 more sourcesComparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis
HIV Medicine, EarlyView.Abstract Objective
This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk +12 morewiley +1 more source
